French Competition Body Fines Janssen €25m For Delaying Generic Durogesic
Janssen-Cilag has been fined €25m by the French competition authority for running a concerted campaign to prevent generic competition to its fentanyl-containing analgesic drug Durogesic. The French medicines regulator does not come out of the affair well either.
You may also be interested in...
The French competition authority has fined Merck & Co's Schering-Plough business €15.3m for attempting to block from the market a generic version of its opioid addiction drug Subutex (buprenorphine).
Sanofi has been fined €40.6 million by the French competition authority for abusing a dominant market position to run a smear campaign against generic versions of its blockbuster antithrombotic Plavix (clopidogrel).
AstraZeneca’s Lynparza can now be used on the Scottish National Health Service for newly diagnosed advanced ovarian cancer.